If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.

Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.

BOSTON, July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology business of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a ...

A University of Oklahoma researcher is the first to discover that the sequence of the genetic defect in the neuromuscular disease Friedreich's ataxia isn't always as uniform as previously thought, a ...

Please provide your email address to receive an email when new articles are posted on . Vatiquinone inhibits 15-Lipoxygenase, which regulates the pathways that Friedreich’s ataxia disrupts. PTC ...

Bill Nye is one of America’s most popular science educators and is now lending his well-known TV persona to a campaign seeking to highlight a rare neurological disease. Known as ataxia, which forms a ...

New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease BOSTON, July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology ...